Clinigen Group (CLIGF) Stock Price, News & Analysis

Company Overview

Clinigen Group plc is a United Kingdom-based pharmaceutical services company that helps make medicines available to patients and healthcare providers worldwide. The company works with pharmaceutical and biotechnology organizations, hospitals, physicians and clinical researchers to manage the supply, access and distribution of medicines, particularly in situations where approved or commercially available treatment options are limited.

Clinigen’s activities have historically included clinical-trial supply, managed access programs and the sourcing and distribution of unlicensed or hard-to-obtain medicines. It has also developed and commercialized specialty pharmaceutical products, including treatments used in areas such as transplantation, oncology and infectious diseases. Its services are designed to support medicines throughout various stages of development and commercialization, from clinical research through routine patient care.

Clinigen served customers and patients across international markets, with operations and commercial activities spanning Europe, North America, Asia-Pacific and other regions. The company was acquired by investment firm Triton in 2022 and subsequently became privately held, ending its public listing on the London Stock Exchange. Clinigen continues to operate as a global provider of specialty pharmaceutical and pharmaceutical-services solutions.

Key Stats

• Today's Range: $8.02 to $8.02
• 50-Day Range: $8.02 to $8.02
• 52-Week Range: $8.02 to $11.56
• Volume: N/A
• Average Volume: 8,620 shs
• Market Capitalization: $1.07 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 9/14/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Private households
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CLIGF
• Previous Symbol: NASDAQ:CLIGF
• CIK: N/A
• Web: www.clinigengroup.com
• Phone: 44-12-8349-5010
• Fax: 01283 495011
• Employees: 1,069
• Year Founded: 2010

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $704.71 million
• Price / Sales: 1.51
• Cash Flow: $1.43 per share
• Price / Cash Flow: 5.60
• Book Value: $4.52 per share
• Price / Book: 1.77

Miscellaneous

• Outstanding Shares: 133,030,000
• Free Float: N/A
• Market Cap: $1.07 billion
• Optionable: Not Optionable
• Beta: 0.49